CRIS
Biotechnology · Healthcare
CFO
Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Curis Inc (CRIS) until August 5, 2022. Curis Inc reported in an 8-K filed August 4, 2022 that Bill Steinkrauss resigned as Chief Financial Officer, effective August 5, 2022. Curis Inc reported in an 8-K filed June 30, 2022 that Bill Steinkrauss resigned as Chief Financial Officer and Chief Administrative Officer (Principal Financial and Accounting Officer), effective August 5, 2022. The same filing states: “Mr. Steinkrauss’s decision to leave his position at Curis is not the result of any dispute or disagreement with the Company or its Board of Directors regarding the Company’s financial reporting or disclosures, accounting policies or procedures or operating practices.” Bill Steinkrauss has spoken on 9 earnings calls across 1 company, most recently for Curis Inc on August 4, 2022. The companies whose calls Bill Steinkrauss spoke on are classified in the Healthcare sector.
“Ms. Duvall succeeds Bill Steinkrauss, who as previously announced is resigning from the company on August 5, 2022, to pursue an entrepreneurial opportunity in consulting.”
“On June 27, 2022, William Steinkrauss notified Curis, Inc. (the “Company”) of his intention to resign from his role as Chief Financial Officer and Chief Administrative Officer (Principal Financial and Accounting Officer) in order to pursue an entrepreneurial opportunity in consulting.”
“Mr. Steinkrauss’s decision to leave his position at Curis is not the result of any dispute or disagreement with the Company or its Board of Directors regarding the Company’s financial reporting or disclosures, accounting policies or procedures or operating practices.”
“Curis continues to execute on its strategy from a place of financial strength.”
“Curis continues to execute on its strategy from a position of financial strength.”
“Before we begin, I would encourage everyone to go to the Investors Section of our website at www.curis.com to find our fourth quarter and year-end 2021 earnings release and related financial tables.”
“For the third quarter 2021, we reported a net loss of $11.1 million or $0.12 per share on both the basic and diluted basis, as compared to a net loss of $6 million or $0.11 per share on both the basic and diluted basis for the same period in 2020.”
“Before we begin, I would encourage everyone to go to the Investors section of our website at www.curis.com to find our second quarter 2021 earnings release and related financial tables.”
Start not stated–2022-08-05
CRIS
Biotechnology · Healthcare
CFO
“Mr. Steinkrauss’s decision to leave his position at Curis is not the result of any dispute or disagreement with the Company or its Board of Directors regarding the Company’s financial reporting or disclosures, accounting policies or procedures or operating practices.”
Curis Inc (CRIS)